Head and neck diseases
PRINCIPAL INVESTIGATORS
- Lorena Arribas Hortigüela
- Marc Oliva Bernal
CLINICAL RESEARCHERS
- Carlos Arranz Obispo
- Ricardo Bartel Arensburg
Josep Oriol Bermejo Segu
Jesús Brenes Castro - Aina Brunet Garcia
- Enric Cisa Lluis
- Mònica Cos Domingo
- Francesc Cruellas Taischik
- Silvia Cuscó Albors
- Maria Foglia Fernandez
- Marta Fulla Campi
- Montserrat Gomà Gallego
- Xavier González Compta
- Miriam Hamdan Zavarce
- Alicia Lozano Borbalas
- Antonio Mari Roig
- Mireia Melero Luque
- Marta Mesalles Ruíz
- Arnaud Morla
- Julio Nogués Orpí
- Anna Penella Prat
- María Plana Serrahima
- Alejandro Portillo Medina
SCIENTIFIC SUPPORT
- Mireia Daura Vidal
- Aina Llenas Bladé
Cancer
Oncobell
Scientific production
27
PAPERS
Average IF: 7,12
7
LED PAPERS
Average IF: 2,40
5 PUBLICATIONS IN FIRST DECILE
14 PUBLICATIONS IN FIRST QUARTILE
20 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Uppaluri,R;Haddad,RI;Tao,Y;Le Tourneau,C;Lee,NY;Westra,W;Chernock,R et al, Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer., N Engl J Med, 2025;393(1):37-50, doi:10.1056/NEJMoa2415434
- Ebrahimi,E;Sangphukieo,A;Park,HA;Gaborieau,V;Ferreiro Iglesias,A;Diergaarde,B;Ahrens,W et al, Cross-ancestral GWAS identifies 29 variants across head and neck cancer subsites, Nat. Commun., 2025;16(1):8787-8787, doi:10.1038/s41467-025-63842-z
- Even,C;Harrington,KJ;Massarelli,E;Laban,S;Fayette,J;Oliva,M;Hesselink,MK et al, Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer, J Immunother Cancer, 2025;13(9):doi:10.1136/jitc-2025-012555
- Bossi,P;Gili,R;Calza,S;Licitra,L;Maddalo,M;Bacigalupo,A;Belgioia,L et al, Validation of a prognostic nomogram for locally advanced oropharyngeal carcinoma treated with intensity-modulated radiotherapy with/without systemic therapy, ESMO Open, 2025;10(11):105859-105859, doi:10.1016/j.esmoop.2025.105859
- del Carpio,LP;Varela,M;Portu,M;Villatoro,S;Purqueras,E;Goma,M;Lorenzo,D et al, Molecular determinants of survival in metastatic uveal melanoma: The impact of SF3B1 mutations, Eur. J. Cancer, 2025;226115591-115591, doi:10.1016/j.ejca.2025.115591
Research highlights
PROJECTS
3 Granted competitive projects
2 Ongoing competitive projects
7 Started clinical trials
36 Ongoing clinical trials
PUBLISHED WORKS
1 Clinical guideline
2 Theses
Selected projects
- BGB-900-102. PHASE 1-2 STUDY INVESTIGATING SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF ANTI-TIM-3 MONOCLONAL ANTIBODY BGB-A425 IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY TISLELIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS. BEIGENE SWITZERLAND GMBH. Budget: 233.370€. 2023- . PI: MARC OLIVA BERNAL.
- MK-7902-009. Estudio clínico de fase 2, aleatorizado, abierto y de tres grupos para evaluar la seguridad y la eficacia de lenvatinib (E7080/MK-7902) en combinación con pembrolizumab (MK-3475) frente a la quimioterapia de referencia y lenvatinib en monoterapia en parti. MERCK SHARP & DOHME ESPAÑA S.A. Budget: 215.055€. 2020- . PI: Miren Taberna Sanz.
- 1456-0001. ENSAYO DE FASE I, ABIERTO, DE ESCALADO DE DOSIS DE BI 1831169 EN MONOTERAPIA Y EN COMBINACIÓN CON EZABENLIMAB EN PACIENTES CON TUMORES SÓLIDOS AVANZADOS O METASTÁSICOS. Boehringer Ingelheim España, S.A. Budget: 201.126€. 2023- . PI: MARC OLIVA BERNAL.
- Optimize: Multiomics signature to customize induction or neoadjuvant treatments for optimizing laryngeal preservation strategies.. Generalitat de Catalunya. Budget: 199.441€. 2026-2029. PI: MARÍA PLANA SERRAHIMA.
- PI25/01316. “INMUNONUTRI: Hacia una Nutrición Oncológica Personalizada – Explorando el Papel de la Caquexia en el Cáncer de Cabeza y Cuello Tratado con Inmunoterapia”. Instituto de Salud Carlos III (ISCIII). Budget: 127.500€. 2026-2028. PI: LORENA ARRIBAS HORTIGUELA.